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Abstract 
 
Ceramics are an extremely versatile class of materials with an extraordinarily broad spectrum of 
applications, ranging from building industry to medicine. Ceramics began to be systematically 
investigated as implantable biomaterials in the 1950s and soon revealed surprising properties. 
Orthopaedics and dentistry are the preferred areas of surgical applications of ceramics, due to their 
suitable strength for load-bearing applications, wear resistance (e.g. alumina and alumina/zirconia 
composites) and, in some cases, bone-bonding ability (e.g. hydroxyapatite and bioactive glasses). 
Another clinical field where ceramics are playing a significant role is oculo-orbital surgery, a highly 
interdisciplinary medical area that focuses on the management of injured eye orbit, with particular 
regard to the repair of orbital floor/wall fractures and/or the placement of orbital implants after 
removal of a diseased eye. Especially in the latter case, implants are not intended for bone repair but 
have to be biointegrated in soft ocular tissues; therefore, suitable ceramics for this application are 
required to go beyond the “traditional” bone-bonding ability. This article provides a picture of the 
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currently-used ceramics for such applications and explores new emerging perspectives, highlighting 
the promises for the future disclosed by the recent advances in nanobioceramics science. 
 
Keywords: Calcium phosphates; Alumina; Bioactive glass; Nanoceramics; Orbital floor repair; 
Orbital implants. 
 
1. Context of application 
 
Oculo-orbital surgery (OOS) is a highly interdisciplinary clinical specialty that involves the tight 
collaboration between maxillofacial and ocular surgeons, with the aim of treating critical patients 
affected by orbital diseases. Our face and eyes are often the first card that we present to others; 
therefore, traumas or pathological diseases involving damage to eye orbit region are associated to 
important societal and psychological issues, including self-acceptance. Recent advances in surgical 
techniques and biomaterials science allow even dramatic cases to be successfully treated with 
excellent postoperative outcomes. In this regard, some types of biocompatible ceramics have been 
proven to be particularly suitable and effective in OOS for the repair of orbital floor (wall) 
traumatic fractures and as orbital implants for anophthalmic patients (Fig. 1).     
External, traumatic impacts to midface, such as blunt injuries, can lead to orbital blowout fractures 
in the inferior or medial thin orbital wall (bone thickness within 200-500 µm) as a result of the 
abrupt increase in intraorbital pressure [1]. A fracture of the orbital floor commonly causes 
herniation of the orbital content (fat and soft tissues) into the maxillary sinus located underneath, 
usually accompanied by enophthalmos1 and/or hypoglobus2. Timing of repair, modality of surgical 
intervention and type of implanted materials used for bone grafting are all critical issues that 
strongly affect the overall outcomes of orbital floor fracture treatment [2,3]. Basically, the scope of 
                                                          
1
 Recession of the ocular globe within the orbit. This disease may be acquired as a result of trauma (e.g. blowout 
fracture of the eye orbit bone) or related to postoperative complications of OOS. 
2
 Downward displacement of the ocular globe; its aetiology and symptoms are quite similar to those observed for 
enophthlamos. 
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the implant is to act as a bone graft ensuring structural support at the bone defect site (fracture); the 
implanted material is often designed as a porous scaffold to promote bone ingrowth and a safe 
anchorage to surrounding host tissues [4]. In this regard, porous hydroxyapatite (HA) and 
HA/polyethylene (PE) composite plates are the most commonly used biomaterials for orbital floor 
and wall repair. 
In the case of severe trauma to the ocular globe, infections non-responsive to pharmaceutical 
therapy or intraocular malignancy (e.g. retinoblastoma in children), removal of the diseased eye 
have to be considered [5]. Orbital implants, often designed as porous spheres of HA, alumina or PE, 
are placed in the patient’s anophthalmic socket at the time of evisceration3 or enucleation4 in order 
to allow adequate volume replacement and transmit good motility to the ocular prosthesis [6,7]. 
Surgical implantation can be facilitated by wrapping5 the implant within a sheet of a smooth 
material, which is particularly recommended for the implants, such as those made of HA, 
characterized by an irregular, rough surface that could erode the conjunctival layer. The motility of 
the aesthetic ocular prosthesis can be improved by placing a titanium peg in the front of the orbital 
implant in order to guide the prosthesis movement in accordance to that of the orbital implant. It has 
been demonstrated that infections following implant exposure6 are more amenable to treatment in 
porous implants compared to non-porous ones (e.g. silicone or poly(methyl methacrylate) (PMMA) 
solid sphere), as vascular ingrowth helps to anchor the implant in situ and permits immune 
surveillance via blood supply. 
 
                                                          
3
 Evisceration involves the removal of the contents of an eyeball, with the sclera and muscle attachments left intact (the 
orbital implant is therefore inserted in the scleral envelope). 
4
 Enucleation involves the removal of the ocular globe from the orbital socket, together with the scleral envelope and a 
portion of the optic nerve, while the conjunctiva, Tenon’s capsule and extraocular muscles are usually spared; this 
procedure is necessary in the case of ocular cancer spread to the sclera. 
5
 Preoperative strategy that involves the wrapping of an orbital implant within a sheet of a smooth material, with the aim 
of facilitating its placement within the soft tissues of the eye socket, diminishing tissue drag and helping precise fixation 
of the rectus muscles to the implant surface. Wrapping is particularly recommended for porous orbital implants in order 
to provide a physical barrier over their slightly irregular porous surface. Suitable wrapping materials include scleral 
autografts and allografts, bovine pericardium and synthetic polymeric meshes. 
6
 Break in the conjunctiva overlying the orbital implant, which may predispose to extrusion of the entire implant. Poor 
surgical technique, excessively large implant size and implant infection may all contribute to this postoperative 
complication. 
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2. Repair of the eye orbit bone 
 
The goal of an orbital floor (wall) implant is to repair the fractured eye orbit bone, lifting the ocular 
globe into its correct position and thus avoiding enophthalmos. Simplifying the problem, the repair 
of orbit bone fractures can be viewed as a special case of bone tissue engineering. An ideal orbital 
bone implant should be (i) biocompatible, (ii) available in sufficient quantities to produce grafts of 
proper shape and size, (iii) strong enough to support the orbital contents and the related compressive 
stress, (iv) easy to be shaped to fit the orbital bone defect, (v) easily fixable in situ, (vi) 
osteoconductive and, if possible, osteoinductive. Progressive degradation in the biological 
environment can be a desirable feature if the material resorption rate is comparable to bone healing 
kinetics and the dissolution by-products elicit minimal foreign-body reaction.  
To find a proper material for orbital floor reconstruction is not an easy task. The first material to be 
routinely used for orbital floor repair was silicone in the form of flexible sheets (commercially 
named Silastic®), introduced in the 1960s by Lipshutz and Ardizone [8]. Since then, a wide number 
of substances of biological or synthetic origin have been experimented in the hope that a truly 
functional biomaterial will eventually materialize. A special subset of ceramics and composites 
appear to be highly suitable due to their favourable physico-mechanical properties and, in some 
cases (e.g. HA, bioactive glasses), osteogenic potential that promotes bone regeneration (Table 1). 
Ceramic and composite implants for orbital bone repair can be fabricated in the form of dense 
plates/sheets or porous structures; in the latter case, pore features typical of bone tissue engineering 
scaffolds are recommended (porosity above 50 vol.%, macropore size of at least 100 µm, high pore 
interconnectivity) [9,10].  
 
2.1. Biological ceramics: bone and HA of marine origin 
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From the materials scientist’s viewpoint, bone itself can be considered a natural ceramic-based 
composite comprising a calcium phosphate matrix (mainly nanocrystalline hydroxyapatite) and an 
organic phase (mainly type I collagen) [11]. 
In the field of orbital bone reconstruction, most surgeons consider autografts from patient’s hard 
tissue as the best option [12,13]. Preferential donor sites include split calvarial bone, maxillary wall, 
mandibular symphysis, antral bone, rib, parietal bone and iliac crest [14-24]; specifically, calvarial 
bone seems the best material especially due to the adequate mechanical suitability [25,26]. The graft 
can be placed as-such [27], fixated by titanium screws and/or plates [28], or used in conjunction 
with a man-made material such as titanium mesh or porous PE [29].  
The advantages of autologous bone are its inherent strength and rigidity usually comparable to those 
of the healthy bone at the fracture site, as well as its vascularisation potential [12]; even most 
importantly, autografts exhibit excellent biocompatibility after implantation. Autologous bone 
grafts are incorporated in living tissue without eliciting any immune reaction to self-antigens, which 
allows foreign body reactions such as infection, extrusion, collagenous capsule formation and 
ocular tethering to be minimized. 
The advantages of using autologous bone in comparison to other options for orbital floor repair 
have been highlighted in many research reports [12,13,30-33]. Rudagi et al. [22] reconstructed 
orbital floor fractures in 11 patients by using autogeneous mandibular symphiseal bone grafts. The 
patients were monitored for 1.5 years postoperatively: a good restoration of the orbital floor was 
reported and extraocular movements were intact in all cases; there were transient complications, 
such as enophthalmos and diplopia7, that resolved spontaneously by few months after surgery. Only 
one patient exhibited symptoms of postoperative infection, that was not associated to the 
autogeneous material but to the titanium plates used for graft stabilization.  
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 Commonly referred to as “double vision”, it can occur when patient’s eyes are not correctly aligned while aiming at an 
object and, therefore, two non-matching images are simultaneously sent to the viewer’s brain. 
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Sakakibara et al. [23] used 1 mm-thick autogenous iliac crest grafts for repairing orbital floor 
fractures in 101 patients. Six months after surgery, computed tomography (CT) scanning showed 
normal orbit morphology and ossification of the transplanted bone grafts; persistent diplopia was 
observed in 15 patients. The authors emphasized the easiness of shaping and cutting the iliac crest 
graft to fit the curvature of the orbit, thanks to material softness, pliability and flexibility. Shetty et 
al. [34] and Ram et al. [35] underlined the particular suitability of autologous bone grafts for the 
repair of large orbital floor defects that required mechanical support on a wide area.       
However, the use of autologous bone is associated with several less favourable aspects. First, it is 
not always easy to contour the harvested bone according to the desired shape and size, which may 
depend on graft source. Furthermore, the graft can break if it is bent beyond its natural capacity: 
therefore, in the case of large defects involving multiple fractures and disruption of bony buttresses, 
other biomaterials are preferred or combined to autologous bone; in this regard, a better accuracy of 
reconstruction can be achieved by using titanium mesh rather than cranial bone grafts [36]. 
Another drawback of autologous bone is its often unpredictable resorption rate, that can vary within 
a quite wide range (from weeks to months) and depends on the graft origin [28,37-39]; for instance, 
cancellous bone is less resistant to resorption than cortical bone due to its porous nature [27].                 
Further problems associated to the use of autologous bone grafts concern the material harvesting 
from a donor site, including significant increase in surgery duration and patient’s time under general 
anaesthesia, and related postoperative complications for the patient (injury to the healthy tissue)  
[22].  
A partial solution to the drawbacks of autografts is the use of allografts (also called homografts), i.e. 
the transplant of bone from cadavers [12,18]. Specifically, the advantages over autologous grafts 
include absence of donor site morbidity, decreased surgery time, opportunity of pre-forming and 
customizing the implant before surgery, and – at least virtually – unlimited availability of grafting 
material (banked bone). However, especially in the past, allografts were associated to the risk of 
disease transmission from donor to patient [40,41] and their use often involved the need for 
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administration of immunosuppressant drugs. Currently, at least in Europe and USA, a wide 
legislation exists and the bone sources are carefully checked before the allograft is released for 
clinical use [42]. A factor that often discourages the use of allografts is their high resorption rate, 
which is statistically higher than that observed with autologous bone implants [22]. 
Occasionally, bone transplant materials from donor animals (xenografts) have also been used. 
Morax et al. [43] implanted bovine bone in a series of 20 patients and found it suitable for the repair 
of orbital fractures: the material was safe and no evidence of biological incompatibility, 
inflammation or infection was detected in the cases examined. However, the use of xenografts is 
potentially associated to disease transmission, severe immunogenic response and unpredictable 
resorption rate, usually higher than that of autologous bone; furthermore, ethical and religious 
issues may apply by the patient. All these factors have discouraged the use of animal bone grafts in 
recent years, also considering that a wide range of other materials and implant options are available 
to surgeons. 
Among ceramics of natural origin, sea coral HA has been widely employed to produce non-
absorbable bone grafts for orbital floor repair. Elmazar et al. [44] compared the efficacy of coralline 
HA porous implants (mean pore size of 400 µm) with that of autologous bone grafts and expanded 
poly(tetrafluoroethylene) (Gore-Tex) for the repair of surgically-induced orbital floor fractures in 
cats. Gore-Tex was more easily shapable and contourable than HA, that showed high brittleness 
involving difficult implantation and loss of integrity postoperatively. Nam et al. [45] compared the 
postoperative outcomes following the use of coral-derived HA (Biocoral®) (191 human patients) 
and PE (214 cases) implants for orbital floor reconstruction. Postoperative enophthalmos was 
statistically more frequent in HA-treated patients with respect to those receiving porous PE, but no 
other significant differences was found postoperatively between the two groups. 
Apart from brittleness, the high cost and some ecological issues (damage to sea coral ecosystem due 
to coral harvesting) are the two other main drawbacks associated to coralline HA implants. 
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The use of algae-derived HA has been recently proposed as a less expensive and more eco-friendly 
alternative to coralline HA. Poeschl et al. [46] evaluated new bone formation and remodelling after 
grafting of the maxillary sinus of 14 patients with an algae-derived HA (AlgOss-C Graft/Algipore) 
implant, with or without the addition of platelet-rich plasma (PRP). Both as-such and PRP-treated 
implants showed good efficacy for bone fracture repair, but statistical evaluation of the samples 
proved significantly better overall resorption of algae-derived HA and increased new bone 
formation when PRP was used as an adjuvant. 
 
2.2. Man-made ceramic implants 
 
In the attempt to overcome the shortcomings of biological HA (inorganic bone matrix and coralline 
HA), powders of chemically-synthesized commercial HA have also been used to produce 3-D non-
absorbable porous scaffolds for orbital floor repair by advanced manufacturing techniques [47-49]. 
Custom-made HA scaffolds can be fabricated through the computer-aided design/computer-aided 
manufacturing (CAD/CAM) approach using the data obtained through CT as a 3-D virtual template 
with high anatomic accuracy. Simon et al. [49] reported the direct-write assembly of 3-D periodic 
scaffolds composed of microporous HA rods arrayed to produce macropores that are size-matched 
to trabecular bone, and highlighted the potential suitability of the produced structures for 
craniofacial and orbital bone reconstruction (Fig. 2). The CAD/CAM-based approach is very 
effective even for the treatment of very dramatic cases: Brie et al. [50] recently applied a 
stereolithographic technique to produce HA custom-made implants for the reconstruction of large 
craniofacial defects (injured area above 25 cm2) with satisfactory cosmetic results both in adults and 
in children. In principle, rapid-prototyped synthetic HA scaffolds represent a good alternative to 
biological ceramics but, like in the case of coralline HA [44,45], implant brittleness (intraoperative 
difficulty of implantation, postoperative loss of structural and mechanical integrity) is still an issue. 
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In order to improve the outcomes following orbital floor surgery, bioactive glasses have also been 
proposed as candidate materials due to their bone-bonding ability and tissue regenerative potential. 
In this regard, a series of studies performed in Finland from the late 1980s to the early 2000s on 
four series of human patients investigated the suitability of cast S53P4 bioactive glass plates (oxide 
weight composition: 53% SiO2, 23% Na2O, 20% CaO, 4% P2O5) for orbital bone reconstruction. 
Suominen and Kinnunen [51] first implanted S53P4 granules and plates at 36 sites in 13 patients 
and compared the behaviour of these materials with that of bone grafts at 16 sites in the same 
patients. Bioactive glass granules were used to treat facial bone defects in subperiosteal pockets and 
to obliterate frontal sinuses, whereas the plates were employed for orbital wall reconstruction. 
Clinical examination, middle face radiographs and CT scanning showed that the bioactive glass was 
generally well tolerated by host tissues. The S53P4 plates retained their density, did not change in 
size and were characterized by tighter contact with the host bone in comparison to glass granules 
and bone grafts. The clinical outcome showed no relapses after a 1-year follow-up and no further 
operations were needed to remove or adjust the material implanted. 
On the basis of these promising results, the studies were continued by Kinnunen et al. [52] who 
compared the use of melt-derived S53P4 glass plates with conventional cartilage grafts for the 
treatment of traumatic orbital floor fractures in 28 patients operated from 1991 to 1995 and evenly 
split in two groups of 14 people. None of 14 patients receiving the S53P4 plate showed significant 
evidence of implant-related postoperative complications; furthermore, their clinical outcomes (only 
1 case of infraorbital nerve paraesthesia and 1 case of entropion8 were registered) were better than 
those of the cartilage group (3 cases of diplopia, 2 case of infraorbital nerve paraesthesia and 1 case 
of enophthalmos). The authors of this study concluded that the use of bioactive glass plates led to 
less morbidity as no donor site operation was needed and S53P4 glass provided favourable healing 
due to its ability to stimulate new bone formation. Aitasalo et al. performed further investigations 
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 Folding inwards of the eyelid (usually the lower eyelid), which causes the eyelashes to constantly rub against the 
cornea. 
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and reported a retrospective study of 36 patients operated from 1995 to 1999 [53]. After a 1-year 
follow-up, the S53P4 glass implants caused no foreign body reaction in the bone or soft tissue as 
well as no infection, haemorrhage and implant displacement/extrusion9; CT scanning qualitatively 
demonstrated new bone ongrowth around the bioactive glass plates. Peltola et al. [54] reviewed the 
postoperative outcomes of 49 patients receiving a S53P4 glass plate from 1998 to 2001 (Figs. 3a 
and b): no signs of implant-related infection, extrusion or displacement were observed over a 2-year 
postoperative follow-up. Furthermore, the implants caused no foreign body reaction, while new 
bone formation was observed around the glass plates and only a minor resorption was found on the 
margins of the implants.  
From the data reported in this series of studies, bioactive glass plates appear a promising and 
reliable solution for orbital floor reconstruction. Specifically, S53P4 glass is biocompatible, able to 
stimulate new bone growth and slowly soluble in the biological environment (thereby ensuring 
adequate structural support while bone regenerates); furthermore, if the glass implant size and shape 
are properly selected, excellent functional and aesthetic results can be achieved. 
It is also interesting to mention a recent work by Tesavibul et al. [55] who fabricated 45S5 
Bioglass® porous scaffolds via a lithographic method. From the preliminary results reported, the 
Bioglass® meshes seem to be enough strong and flexible to be implanted in orbital floor defects, as 
suggested in Figs. 3c and d.     
 
2.3. Composites and mouldable ceramic pastes 
 
Apart from being processed in the form of single-phase macroporous structures, HA was also used 
for manufacturing HA/PE composite implants, that have been marketed under the commercial name 
of HAPEX® since more than 20 years and successfully adopted as a bone replacement material in 
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 “Extrusion” is the commonly used surgical term describing the expulsion or spontaneous removal of an (ocular) 
implant from the host tissue, without any connotation of its meaning in polymer technology. 
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otology (middle ear ossicles prosthesis) [56] and orbital floor repair (Fig. 4) [57-60]. The 
combination of stiff, osteoconductive but brittle HA with low-modulus, tough and bioinert PE 
produces a biomedical composite exhibiting attractive properties for bone substitution [58-60]. 
These composite implants allow bone ongrowth and ingrowth to occur (if produced as porous 
scaffolds) but are not reabsorbed by the organism, thus remaining permanently in situ. 
In 2010, Asamura et al. [61] produced a 4-layer composite construct by joining a periosteum graft 
to a HA/poly(L-lactic acid) PLLA/polycaprolactone (PCL) sheet. This composite biomaterial was 
implanted in human patients suffering from orbital floor fractures; autologous iliac crest bone was 
also implanted in a control group. The anatomical position and movement of the eyeball were 
postoperatively normal in both groups; therefore, this multilayer composite was suggested as a 
promising alternative to autologous bone, thereby overcoming the problems of limited autograft 
availability and possible morbidity at the donor site. 
Landes et al. [62] recently treated a group of patients with midfacial bone fractures, including a few 
cases needing orbital floor repair, with an internal fixation HA/PLLA composite device; bone 
ingrowth into the implant was observed and minimal postoperative complications were reported 
over a 67-month follow-up. 
Since about 25 years, HA and other calcium phosphates are also commercially available in the form 
of mouldable pastes, commonly termed as “bone cements”, to be used in the broad field of cranio-
maxillofacial reconstruction [63-66]. HA cement is composed of tetracalcium phosphate and 
dicalcium phosphate (anhydrous); in the presence of water and at physiological pH, the salts react 
isothermically to produce a dense paste that can then be shaped intraoperatively. The reactants are 
then reprecipitated until the entire material is converted to finely porous HA, which takes 
approximately 4 to 6 h in vivo. The setting time can be properly modulated according to specific 
surgical needs; for instance, it was observed that mixing the HA cement in 0.25 M sodium 
phosphate buffer decreased the setting time significantly [67]. Mathur et al. [68] reviewed the use of 
HA cements in craniofacial surgery, including orbital floor and wall repair, and concluded that such 
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materials are excellent options for reconstruction in the clean field. However, the existing literature 
suggested that exposure to sino-nasal or oral cavity – which is the case of orbital floor repair, as HA 
cement is exposed to the environment of the maxillary sinus – may predispose the implant to 
infection (bacteria may migrate from the external environment to the implant surface), and therefore 
the material should be used cautiously in these situations. 
Apart from HA, other calcium phosphates have been occasionally proposed as implantable 
materials for orbital bone repair. Reyes et al. [69-71] fabricated porous biphasic β-tricalcium 
phosphate (β-TCP)/HA plates (weight ratio β-TCP/HA = 77 : 23) by the sponge replica method and 
implanted them in cats as orbital floor grafts. These scaffolds were highly biocompatible and did 
not elicit any kind of adverse postoperative complications; furthermore, their porous network (mean 
pores size of 198 µm) allowed fibrovascular tissue ingrowth to occur inside the implant, thereby 
increasing its stability in situ. 
Van Leeuwen et al. [72] fabricated β-TCP/poly(trimethylene carbonate) (PTMC) composite sheets 
(thickness around 1.0 mm) through co-precipitation followed by compression moulding and 
suggested their suitability as materials for orbital floor repair; specifically, the effect of different 
amounts of the ceramic component (15 and 30 vol.%) on the properties of the composite was 
investigated. Lamination of the composites with minimal amounts of poly(D,L-lactic acid) 
(PDLLA) was also experimented, as the reconstruction of large defects might necessitate the use of 
more rigid materials (the elastic modulus of PDLLA is above 2500 MPa, whereas that of PTMC is 
within 5-7 MPa). The flexural modulus of the composites reached 17 MPa when introducing 30 
vol.% of β-TCP. A laminate of this composite incorporating a PDLLA sheet (total thickness 1.0 
mm) had a flexural modulus of 64 MPa. These results suggested that, from a mechanical viewpoint, 
these laminated composite sheets can be suitable for orbital floor reconstruction. The authors 
hypothesized that, after implantation in situ, the polymer component resorbs enzymatically without 
the formation of acidic compounds, while the ceramic phase can induce bone formation. 
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Chen et al. [73] evaluated a biomaterial combining biphasic calcium phosphate (HA and β-TCP) 
with single-donor allogeneic fibrin glue in 10 patients with a follow-up of 4 years. The fibrin-rich 
biomaterial was easy to mould and apply on the surgical site, allowing the surgeon to sculpt 
accurately the bone defect and providing adequate mechanical stability. No infection of the eye 
orbit or implant extrusion were observed. Ocular motility was normal, and no diplopia or 
enophthalmos of the injured orbit was noted. CT scans of the reconstructed orbits revealed good 
restoration of the orbital floor defect in all 10 patients. On the basis of these promising results, the 
authors of the study suggested that the use of a fibrin-rich calcium phosphate biamaterial offers a 
valuable alternative to autologous cranial bone graft or titanium mesh in the reconstruction of 
orbital floor bone defects. 
It is worth pointing out that, unlike HA implants, β-TCP-containing ceramics are characterized by a 
certain degree of solubility, which should be taken into account in view of the maintenance of an 
adequate structural and mechanical integrity while new bone tissue regenerates.   
Among the ceramic/polymer composites proposed for orbital floor repair, Proplast II (a 
polytetrafluoroethylene (Teflon) fibres/alumina implant) was also reported with good outcomes in 
one study by Shah et al. [74]. Specifically, Proplast II was used to manufacture subperiosteal 
implants for the correction of anophthalmic enophthalmos in 34 patients who had poor orbital 
volume replacement after insertion of a spherical orbital implant. However, since the late 1990s 
Proplast II had progressively fallen into disuse because of adverse effects associated to its use in 
other surgical applications [75]. 
 
3. Orbital implants 
 
Since the ancient Roman age a number of materials, including wool, clay, gold and silver, have 
been used to manufacture orbital fillers, often painted or enamelled to mimic the natural iris of the 
contralateral eye, with the aim of replacing the anophthalmic socket volume and restoring an 
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acceptable aesthetic appearance to the patient’s face [7]. Serial production of artificial eyes dates 
back to the end of the 18th century, when Venetian glassmakers began to fabricate implantable 
blown glass spheres, that however were brittle and had poor fit and little comfort [76]. 
The modern era of anophthalmic socket surgery started in 1885, when Mules first described in 
detail the surgical placement of a hollow glass sphere into an eviscerated globe [77]. In the early 
1900s, orbital implants coupled with external ocular prostheses (both made of glass) began to be 
adopted due to better postoperative outcomes and overall comfort of the patient. The prosthesis was 
a coloured glass shell placed between the closed conjunctival surface covering the orbital implant 
and the eyelid. The battle casualties of the First World War increased the need for artificial eyes, 
and from 1920 to 1940 Germany became the main supplier of glass orbital implants due to the 
superior glass blowing techniques [7]. A study involving 52 human patients and published by Burch 
in the mid 1940s estimated failures in less than 10% of cases using glass orbital implants [78]. The 
battle casualties of the Second World War (WWII) caused again a large demand of artificial eyes, 
but the wartime shortage of glass eyes imported from Germany led to the development of PMMA 
orbital devices in the USA. Acrylic implants overcame the drawbacks of glass implants (brittleness 
and chemical etching by body secretion) and permitted custom fitting at a relatively low cost as well 
as better motility of the prosthesis due to a new design for improved attachment of extraocular 
muscles [79]. Since the 1950s till now, a variety of biomaterials have been experimented in the 
search of an ideal orbital implant; among them, porous ceramics of biological or artificial origin 
seem to be particularly suitable (Table 2).  
An ideal orbital implant should display a number of characteristics, including (i) material 
biocompatibility, (ii) adequate socket volume replacement, (iii) good motility transmitted to the 
ocular prosthesis, (iv) adequate support to the ocular prosthesis, (v) low cost, (vi) easiness of 
implantation and (vii) non-degradability over time. The presence of an interconnected network of 
macropores in the 300-500 µm range is a highly desirable feature that allows implant 
fibrovascularization, defined as the postoperative ingrowth of viable vascular connective tissue. 
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Tissue growth into a porous orbital implant offers several key advantages including a very low 
extrusion rate and a reduced risk of implant infection due to the presence of an adequate blood 
supply. It was also observed that, with sufficient time for fibrovascularization to occur, any 
exposure due to the abrasion of the conjunctiva by the implant surface may heal spontaneously due 
to the good blood supply within the implant.  
Moreover, fibrovascularization carries an additional advantage. Looking at the historical evolution 
of orbital implants, previous attempts to establish a direct mechanical connection between non-
porous orbital implants (e.g. a simple polymeric sphere) and the aesthetic ocular prosthesis had been 
invariably met with the development of infections (due to bacterial colonization of the implant 
region connected with the prosthesis), exposure and other complications. Thanks to the 
fibrovascularization of porous implants, it is possible to drill a hole in the implant and to insert a 
peg between implant and ocular prosthesis. The presence of a good blood supply allows the drilled 
area to re-epithelialize with conjunctiva: thus, the implant remains separated from the external 
environment by the living conjunctival layer but retains a direct connection to the prosthesis, 
thereby providing enhanced motility (the ocular prosthesis can more closely follow the movement 
of the contralateral eye) without exposure of the implant and relevant complications. Significant 
improvement of both vertical and especially horizontal excursion of the artificial eye has been 
reported for pegged HA implants with respect to unpegged ones [80]. 
 
3.1. Implants based on apatites of biological origin 
 
As an alternative to brittle glass implants, small spheres of natural ivory from elephant’s tusks were 
experimented as orbital implants in a few human patients in the first half of the 20th century [81]. 
Formally, ivory is a ceramic-based biocomposite made of nano-sized apatite crystals (about 70 
wt.%) hold together by a complex network of type I collagen fibres that are eliminated after the 
animal’s death. This type of non-porous orbital implant was rapidly replaced by porous spheres of 
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bovine cancellous bone, that were heat-treated to destroy all organic matter, thereby leaving only 
the calcium phosphate mineral framework [82-84]. These porous apatite implants were widely used 
before the WWII and recommended as “the most satisfactory of all orbital implants” in the Spaeth’s 
treatise [81]. 
After a hiatus of about 30 years, corresponding to the development and spreading of polymeric 
orbital implants, in the 1970s a group of researchers coordinated by Dr. Molteno and working in 
New Zealand resurrected the idea of an implant based on natural bone apatite. Reviewing the 
available literature, Molteno and co-workers noted that the postoperative exposures of bone-derived 
HA spheres used till the WWII were generally rare, small and frequently tended to heal 
spontaneously, which did not occur upon implantation of a polymeric device. This behaviour 
suggested that the biodegradable nano-crystalline HA matrix of bone would constitute a superior 
orbital implant since, once organized by host connective tissue, it would not migrate through the 
tissues while any small exposures would heal spontaneously. Furthermore, the mass of host 
connective tissue incorporating the bone mineral implant would likely remain unchanged for the 
patient’s whole life. The early trials of this type of implant (the so-called “Molteno M-Sphere”) 
involved the use of deproteinized bone of calf fibulae and confirmed that the mineral matrix of 
cancellous bone was readily incorporated into the tissues; furthermore, small exposures were 
followed by spontaneous crumbling of the exposed bone with healing of the overlying conjunctiva 
[85,86]. A study involving 52 human patients with good follow-up over a 10-year period was 
reported in 1991 [87], and the long-term successful outcomes of other 120 M-Sphere orbital 
implants inserted after enucleation between 1977 and 2000 were later documented [88]. This 
implant is significantly more porous (around 80 vol.%) than other available HA orbital spheres (50-
65 vol.%); the use of a lighter device is an advantage leading to decreased stress on the lower lid 
and associated ectropion10 formation. However, due to the high porosity (Table 3) the M-Sphere 
orbital implant is brittle and may be unable to support a peg [89,90]. This drawback, together with 
                                                          
10
 Turning out of the lower eyelid with exposure of its inner surface. 
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the high cost (around 500 €, significantly higher than that of polymeric implants) and ethical issues 
by some patients who did not accept an animal-derived implant, may have contributed to limit its 
diffusion. 
In the last 1980s, Perry [91] and Dutton [92] independently pioneered the use of coralline porous 
HA spheres (Bio-Eye®) in anophtalmic surgery with excellent postoperative outcomes. The 
interconnected porous structure of the HA implant (Table 3) allowed host fibrovascular ingrowth, 
which potentially reduces the risk of migration11, extrusion and infection [92]. Furthermore, 
coralline HA is strong enough to support a peg in the frontal area of the implant, thereby ensuring 
connection to the aesthetic ocular prosthesis with more life-like motility. 
However, the use of coralline porous HA implants is associated to some drawbacks [5,6,79], 
including damage to marine ecosystems due to the harvesting of natural corals and high cost 
(around 600 €) compared to other options such as non-porous silicone or acrylic spheres (around 50 
€). Furthermore, being a porous ceramic, its brittle nature precludes suturing the extraocular 
muscles directly to the implant [6,93]; therefore, pre-operative placement of the HA implant within 
a sheet of soft material (e.g. donor sclera, polymeric meshes) is necessary for muscles attachment. 
Furthermore, there is convincing evidence that the rough surface of coralline HA implants may 
contribute to the development of late exposure due to the abrasion of the relatively thin conjunctiva 
and Tenon’s capsule as the implant moves. Therefore, also for this reason HA implant wrapping 
within a sheet of soft material is strongly recommended [94,95]. On the other hand, it was also 
shown that the majority of exposed HA implants can be successfully treated by using patch grafts of 
different origin (e.g. scleral graft, dermis graft, oral mucosa graft) without the need for implant 
removal [96-98]. In case of orbital implant infections associated to exposures, administration of 
systemic antibiotics and topical eye drops should be carried out; if no symptoms improvement is 
noticed, implant removal should be considered [99]. Other reported complications include 
                                                          
11
 Postoperative change in position of the implant. 
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conjunctival thinning (followed or not by exposure), socket discharge, mid-term to chronic infection 
of the implant, persistent pain or discomfort, and peg extrusion from drilled HA implants [100-104]. 
In the search for an “ideal” porous orbital implants with a reduced complication profile and 
diminished surgical and postoperative costs, alternative materials such as porous synthetic HA and 
alumina have been investigated over the last two decades. 
 
3.2. Synthetic ceramic implants 
 
Orbital implants made of chemically synthesized HA, such as the so-called FCI3 sphere, began to 
be commercialized in the early 1990s as a less expensive alternative to coralline HA (Fig. 5). These 
implants have analogous chemical composition to that of the Bio-Eye® [105], although scanning 
electron microscopy (SEM) investigations revealed some differences in terms of porous architecture 
(lower porosity: 50 vs. 65 vol.%; decreased pore size uniformity; presence of blind pouches and 
closed pores [106,107]) and size of the surface crystals (Table 3); nonetheless, implant 
interconnectivity (Fig. 6) is still sufficient to allow central implant fibrovascularization [108]. FCI3 
implant is less expensive than the Bio-Eye® (400 vs. 600 €) and easier to drill for peg placement 
(due to lower porosity); however its shortcomings, in terms of risk of conjunctival abrasion and 
postoperative exposure, are substantially analogous to those of coralline HA. 
A new type of synthetic HA orbital implants with 75 vol.% porosity and macropore size ranging 
from 100 to 300 µm was recently experimented by Kundu et al. in India [109-112]. HA powder was 
synthesized by a wet chemical method, calcined at 800 °C and then intimately mixed with an 
appropriate quantity of naphthalene particles (mean size of 300 µm). The powder blend was 
compacted by cold-isostatic pressing to form cylindrical “green” bodies that were subsequently 
machined to fabricate the orbital implants. By heating at 80 °C, the naphthalene was driven off from 
the green samples with great care to prevent cracking and, finally, a thermal treatment at 1250 °C 
allowed the HA particles to sinter and the mechanical properties to increase (compressive strength 
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around 10 MPa) [109,112]. A detailed investigation of the mechanical properties and in vitro 
biocompatibility (L-929 mouse fibroblasts cells and rabbit corneal epithelial cell line) was carried 
out with encouraging results [112]. The implants were also tested in vivo in Mongrel dogs [110] and 
human eviscerated/enucleated patients [111]. The available results from clinical trials are 
promising, but these studies are still too limited (30 patients in all, 2.5 years of follow-up [110,111]) 
to draw definite conclusions on their long-term safety and efficacy. 
Low-cost versions of synthetic HA orbital implants are also available on the market, especially in 
some emerging countries; however, they exhibit a number of drawbacks that strongly limit their 
economic advantage over the other commercially-available options. Some of these implants have 
been reported to contain CaO impurities that, after hydration in host tissues, may form Ca(OH)2, 
which is caustic [113]. Other implants have higher weight, lower porosity (below 50 vol.%) and 
lower pore interconnectivity than FCI3 devices, with consequent limited fibrovascularization and 
enhanced risk of implant migration [114]. 
Porous alumina (Al2O3) orbital implants (the so-called “Bioceramic sphere”), approved for clinical 
use by FDA in 2000, seem very promising in overcoming the drawbacks of porous HA devices. 
Although the cost of an alumina orbital implant is still quite high (slightly higher than that of FCI3 
sphere), it has a lower tendency to exposure/extrusion due to the smoother surface with 
submicrometric grains (Table 3), which results in a diminished risk of postoperative complications.  
Alumina implants were first experimented in 16 eviscerated rabbits by Morel et al. [115], who 
observed only one postoperative infection without conjunctival breakdown; furthermore, 
fibrovascular ingrowth started 15 days postoperatively, reached the core of the implant and was 
complete after 1 month. These promising results were confirmed in a subsequent study by Jordan et 
al. [116], who compared the performance of alumina and coralline HA implants in rabbits and 
highlighted that the new alumina implant was as biocompatible as HA, less expensive and its 
manufacturing did not involve any damage to marine life ecosystems as may occur in the case of 
BioEye®. 
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An accurate comparison about the proliferation of orbital fibroblasts in vitro after exposure to 
Bioceramic implant and other three implants made of different materials (coralline HA, synthetic 
HA, porous PE) was reported by Mawn et al. [117]. The proliferation of fibroblasts differed on the 
various implants studied and, specifically, was maximum on the Bioceramic implant. Furthermore, 
the fibroblasts growing on the Bio-Eye®, FCI3 and PE implants all had debris associated with them, 
whereas the alumina implant was free of these debris, which was mainly attributed to its finely 
crystalline microstructure (Table 3). These findings were later substantially confirmed by Choi et al. 
[118] 
Promising results were also published in 2002 by Akichica et al. [119], who implanted pieces of 
alumina with 75 vol.% porosity in the eye sockets of albino rabbits. There were no signs of implant 
rejection or prolapse of the implanted material over a 8-week follow-up; four weeks after 
implantation, fibroblast proliferation and vascular invasion were noted, followed by tissue ingrowth 
after 2 months.  
The first outcomes of Bioceramic implant in humans (107 patients over a 3-year follow-up) were 
reported by Jordan et al. in 2003 [120]. Postoperative problems encountered with its use were 
substantially similar to those observed with HA orbital implants but appeared to occur rarely; the 
incidence of exposure associated with the Bioceramic implant was significantly lower than that 
reported for the HA ones, and infections did not occur in any patient. In a following study the same 
research group further confirmed that alumina implant infections are rare [121] and, after reviewing 
a clinical case series of 419 patients who received a Bioceramic orbital implant, estimated an 
implant exposure rate of 9.1% with most exposures occurring after a 3-month follow-up period 
[122]. Wang et al. [123] reported that exposures of Bioceramic implants occurred only after long-
term follow-up and were preferentially associated with evisceration, pegging and prior ocular 
surgeries, whereas no late side effects were found in enucleated eyes. Successful treatment of 
exposures, without the need for implant removal, were performed by covering the exposed alumina 
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area with appropriate patches of biological origin (e.g. retroauricular myoperiosteal graft containing 
myofibrovascularized tissue) [124,125]. 
In recent years, bioactive glasses and glass-ceramics were also experimented as candidate materials 
in the manufacturing of porous orbital implants. A group of Chinese researchers implanted 
bioactive glass-ceramic porous orbital implants in enucleated rabbits and observed no rejection 
during a 6-month postoperative follow-up [126]. Ultrasound examination revealed a venous-flow-
like spectra in the implants after 3 months and histological analysis showed that around 90% of the 
implant pores were filled by fibrovascular tissue after 6 months from operation. Encouraged by 
these promising results, the same authors implanted glass-ceramic orbital devices in 102 human 
patients, declaring a success rate of 96.1% (98 cases) [127]. In 4 cases the conjunctiva was torn 
partly when suture stitches were taken out of the wound, and 1 patients needed the implant removal. 
There were no reported complications after a follow-up of 6 months to 2 years and all patients were 
satisfied with their cosmetic appearance, even in those cases in which implant pegging was not 
performed as a secondary procedure to further improve the motility of the ocular prosthesis. 
The use of bioactive glass to fabricate orbital implants was also cited by Richter et al. in a patent 
deposited in 2009 [128], but no manufacturing or clinical studies have been reported yet on this 
type of implant. 
A special mention has to be dedicated to Biosilicate®, an interesting set of bioactive glasses and 
glass-ceramics belonging to the SiO2-CaO-Na2O-P2O5 quaternary system [129,130]. Biosilicate® 
was originally developed by the Zanotto’s research group in Brazil (late 1990s) and proposed as a 
multipurpose biomaterial with a number of possible applications that range from bone/dental repair 
to orbital implants. A study published in 2012 by Brandao et al. [131] aimed to assess the 
biocompatibility of Biosilicate® and 45S5 Bioglass® in rabbit eviscerated sockets. Fifty-one Norfolk 
albino rabbits underwent evisceration of the right eye followed by implantation of dense (pore-free) 
cones made of 45S5 Bioglass® (control group) and two types of Biosilicate® into the scleral 
envelope. The Biosilicate® materials implanted were two glass-ceramics containing one 
22 
 
(1Na2O.2CaO.3SiO2, Biosilicate® I) or two crystalline phases (1Na2O.2CaO.3SiO2 and apatite, 
Biosilicate® II). During the experimental period (180 days), no animals presented orbital infection 
or implant migration/extrusion, and the morphological analysis revealed pseudocapsules around all 
of the implants. The 45S5 Bioglass® and Biosilicate® I implants induced lower inflammation and 
less pseudocapsule formation than the Biosilicate® II. Seven days after the surgical procedure, the 
inflammatory reaction reached the maximum and then gradually diminished throughout the 
experiment for all groups, especially the 45S5 Bioglass® group. The same researchers obtained 
analogous results in a second study carried out in 45 eviscerated rabbits [132]. On the basis of these 
findings, it was suggested that 45S5 Bioglass® and Biosilicate® implants could be alternative 
materials to manage the anophthalmic socket, the best responses being obtained with 45S5 
Bioglass® and single-phase Biosilicate® cones with no signs of systemic or local toxicity in the orbit 
of eviscerated rabbits. 
Clinical studies in human patients are currently on going in the framework of a research project 
coordinated by Dr. Artioli Schellini (FAPESP grant no. 13/00131-8) in Brazil (Faculdade de 
Medicina de Botucatu and Faculdade de Medicina of the USP Sao Paulo). Sixty patients who 
underwent evisceration or enucleation are being recruited; the study was designed in such a way 
that 40 patients receive Biosilicate® cones, while the control group (20 patients) is implanted with 
PMMA cones. After surgery, patients are being subjected to follow-up after 7, 15 and 30 days, and 
thereafter at two-month intervals for a period of six months. Systemic parameters to be evaluated 
include clinical examination (evaluation of the orbital cavity and changes in vital organs), 
biochemical and toxicological tests, and CT analysis of the orbit. Clinical trials are expected to 
conclude by 2015; at present, mid-term results have not yet been published. 
Heringer and Ng also reported an interesting use bioactive glass to fill old peg tracts and permit re-
pegging of porous HA orbital implants, if the initial drilled tunnel was not perpendicular and central 
to the implant surface [133]. This strategy has been applied in 3 human patients who had persistent 
problems with their pegged HA orbital implants and did no longer respond to conservative 
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treatment. After removal of the old peg, the hole was partially filled with bioactive glass and, after 2 
months, 2 patients also underwent successful re-drilling of the implant followed by insertion of a 
new titanium peg, with satisfactory connection to the ocular prosthesis and absence of 
complications over a 3-year follow-up. 
 
3.3. Composites and coatings 
 
From the surgeon’s viewpoint, the use of stiff orbital implants, such as the ceramic ones, is helpful 
during the operation as the implant can be easily handled and placed into the anophthalmic socket 
with high precision and control on its position. However, compliance mismatch between the orbital 
implant material and the surrounding soft tissues, in combination with the repetitive movement of 
the implant by the extraocular muscles, can contribute to inflammation and necrosis of 
conjunctival/scleral layers, which eventually lead to implant exposure. 
In the attempt to overcome these problems, orbital implants fully made of polymeric material (e.g. 
porous PE sphere) as well as ceramic/polymer composites have been proposed over the years and, 
in some cases, clinically tested in human patients.  
In the late 1970s a felt-like composite, called Proplast I, gained a certain popularity in maxillofacial 
and orbital surgery due to its easy pliability and shapability. Proplast I was constituted of 
polytetrafluoroethylene and carbon fibres and, once implanted, could be invaded by fibrovascular 
tissue thereby diminishing the risk of implant extrusion [134]. The clinical studies carried out in 
patients who received Proplast I hemispherical orbital implants were promising, with no cases of 
migration or extrusion after a 2-year follow-up [135]. In recent years, however, Proplast I has 
progressive fallen in disuse because of long-term postoperative complications, primarily late 
infections, associated with its use [136]. 
In the 1980s, the implantation of porous enucleation implants made of Proplast II, an evolution of 
Proplast I, was reported. This new device was different from its predecessor in the composition 
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(Proplast II was an alumina/polytetrafluoroethylene composite) and in having a pore-graded 
structure (a porous anterior portion and a siliconized non-porous posterior surface to allow 
smoother movements) [137,138]. Proplast implant II had a nipple on its anterior surface (lined by 
the patient’s conjunctiva) that could integrate with a depression on the posterior surface of the 
ocular prosthesis. Several Proplast implants II required removal by few postoperative months 
because of poor motility and, over histopathological examination, were found to be completely 
avascular and surrounded by a thick fibrous pseudocapsule [139]; therefore, in recent years the use 
of Proplast II to fabricate orbital implants has been abandoned.  
In the early 1990s, a group of German researchers developed a composite orbital implant 
comprising a hemispherical anterior part made of synthetic porous HA to guarantee tissue 
integration joined to a posterior part of silicone rubber; the horizontal and vertical eye muscles were 
sutured cross-wise in front of the implant to ensure better stability and motility [140]. Overall 
implant biocompatibility was excellent and the transmission of the motility to the ocular prosthesis 
was generally acceptable [141,142]. At present this implant is mainly employed in Europe; its 
diffusion is limited due to the high cost and complex surgical procedures needed for its implantation 
compared to porous spheres made of HA, alumina or PE. 
In a couple of recent reports, bioactive glass-coated PE porous spheres were experimentally 
implanted in enucleated rabbits [143] and human patients [144] to investigate the effect of bioactive 
glass on the  fibrovascular ingrowth within the implant pore network. In both studies, the inclusion 
of bioactive glass particulate did not seem to significantly promote the rate of fibrovascularization, 
and probably this is the reason why the investigations were apparently discontinued. 
The clinical effects of a calcium phosphate coating on the struts of porous alumina implants were 
also investigated in a few studies over the last 15 years. A group of Korean researchers first 
fabricated this new type of implant by means of the polymer sponge replication method: the porous 
alumina skeleton acted as a load-bearing structure, while a 20-µm thick HA layer deposited on it 
was advocated to provide superior biocompatibility and better long-term stability in the eye [145]. 
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Animal studies in eviscerated rabbits receiving 12-mm sized HA-coated alumina spheres with 
different pore sizes (300, 500 and 800 µm) revealed peripheral fibrovascularization of the implant 
in all groups after 15 postoperative days and also at the center of the implant after 28 days; 
fibrovascularization was more predominant in the group of implants having 500-µm pores 
compared to the other two types [146].  
In 2002 Jordan et al. [147] reported a comparative study on the implantation of experimental 
alumina implants coated with HA or calcium metaphosphate in rabbits. Both types of implant had 
multiple interconnected pores and, in comparison to the uncoated device, the coatings increased the 
size of the trabeculae from 150 to 300 µm; therefore, the pores appeared smaller but still ranged in 
the 300-750 µm range. There was no clinical difference in the socket response between coated or 
uncoated implants and fibrovascularization occurred uniformly throughout each implant over a 12-
week follow-up. 
A few years later, Chung et al. [148] investigated the fibrovascular ingrowth and fibrovascular 
tissue maturation of HA-coated porous alumina implants in comparison with commercial HA 
spheres in enucleated rabbits over a 24-month follow-up without finding any significant difference 
between the two groups.  
No other studies about HA-coated implants have been published; probably, the absence of a clear 
advantage from a clinical viewpoint (HA coatings did not appear to facilitate or inhibit 
fibrovascular ingrowth with respect to uncoated implants) and the presence of significant amounts 
of CaO as a contaminant (related to the coating manufacturing) [147] discouraged the researchers 
from performing further investigations in this direction.   
 
4. Emerging perspectives: the role of surface nanostructure and the potential of nanoceramics 
 
Many experimental studies have demonstrated that cell-substrate interactions at the micro- and 
nano-scale can be regarded as one of the major factors ultimately determining the long-term 
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performance of biomaterials once implanted in vivo [149]. A valuable publication by Jones provides 
interesting insights on the importance of bioceramic and composites nanostructure [150]. Most 
studies on the topography of biomedical materials have been carried out in the context of bone 
tissue engineering, and there is convincing evidence that osteoblasts preferentially adhere to and 
spread on finely microrough surfaces [151,152]. In this regard, implants made of biological or 
synthetic HA appear to be very suitable for the repair of orbital bone fractures as their micro-/nano-
crystalline surface can favour colonization by bone cells. New perspectives could emerge from 
bioactive glasses, as their surface roughness can be tailored, for instance, by changing the size of 
the starting glass particles and/or the sintering parameters to modulate the crystal size. Recent 
studies have also demonstrated that cells directional growth and alignment can be also induced and 
properly modulated by means of a nanogrooved surface, as schematically illustrated in Fig. 7 [153].  
In the field of orbital implants, The group of Dr. Jordan [106] and Choi et al. [118] used SEM to 
investigate the microstructural features of coralline HA, synthetic HA and alumina porous spheres; 
they also provided a comparison with other polymeric devices available on the market. As shown in 
Table 3, the materials analysed reveal marked variations of crystal size/shape and surface 
topography. The authors of these studies suggested that surface roughness could influence the 
inflammatory response after implantation and crystal size could determine the material-induced 
phagocytic response. It was observed that ceramics with crystal size around 2-3 µm (coralline and 
synthetic HA) showed greater tissue reaction in comparison to implants with finer grain (alumina). 
In this regard, it was suggested that surface crystals of larger size increased phagocytic activation, 
consistently with the findings by Nagase et al. [154] who showed that smooth HA crystals are 
associated with less inflammation than sharp-edged crystals. From these results it is still impossible 
to unequivocally claim that one porous ceramic implant is clearly superior to the others, even 
though alumina, exhibiting excellent biocompatibility and favourable microstructural features, 
seems a promising candidate. 
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An additional issue to consider is the effect of micro- and nano-scale topography on bacteria, since 
cells may have to compete with pathogens in the ocular environment. Some studies suggest that the 
surface topography of ceramic implants could be purposely designed to encourage cells to colonize 
while limiting bacterial adhesion and risk of infection [149]. This strategy could involve the use of 
micro- and nano-fabrication techniques and/or the optimization of sintering temperature and time to 
develop crystals with a specific size, thus creating a customized surface roughness. On the other 
hand, it has been widely showed that, especially in the case of orbital implants, surface macro- and 
micro-roughness is responsible of conjunctival abrasion, which may lead to implant exposure with 
the associated risk of bacterial colonization. In this regard, the use of non-crystalline ceramics with 
a smooth surface, such as bioactive glasses, could be highly desirable. Usually, bioactive glasses are 
processed to obtain macroporous scaffolds through a high-temperature thermal treatment of 
sintering, accompanied by partial devitrification of the material occurs with formation of a 
superficially rough glass-ceramic [155-161]. However, few interesting exceptions can be found in 
the literature: for instance, Fu et al. [162] produced 13-93 bioactive glass scaffolds by heat 
treatment at 700 °C to densify the glass network, thus forming strong porous constructs without 
crystallizing the material. 
Bioactive glasses can be a very valuable resource in OOS, but their composition should be carefully 
designed: if a bioactive and even resorbable glass can be desirable for the repair of eye orbit bone 
fractures, a glass with minimal chemical/biological reactivity in vivo and able to persist in situ 
indefinitely should be used for orbital implants [163].      
In a few recent studies, the use of nanoceramics and nanocomposites, also in the form of coatings 
on pre-existing devices, has been experimentally proposed in the context of OOS. Patel et al. [164] 
incorporated HA nanoparticles (size in the 20-70 nm range) within cyclic acetal hydrogels to create 
nanocomposites that were used to repair surgically-created orbital floor defects in rabbits. Some 
evidence has shown that nano-sized HA particles exhibit superior osteoconductive ability compared 
to conventional microcrystalline HA [165], which would be a highly desirable property for the fast 
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healing of critical orbital defects. Histomorphometric results indicated that the nanocomposite 
material elicited a positive in vivo response in terms of bone growth; however, in this preliminary 
study complete restoration of orbital floor defects was not achieved after 28 days of implantation.  
Ye et al. [166] coated macroporous HA orbital implants with a thin layer of CuO-containing 
mesoporous bioactive glass (Cu-MBG) (Fig. 8). The aim of this research was to combine the 
antibacterial effect of released Cu2+ ions [167] and the local drug delivery capacity of the 
mesoporous glass coating [168]. Cu-MBG coatings with 0, 2 or 5 mol.% of CuO were prepared by 
dipping the porous HA implants into the sol precursor of the mesoporous glass, followed by 
evaporation, ageing and calcination. With the peculiarity of releasing antibacterial ions as the Cu-
MBG degrades (viability of S. Aureus and E. Coli was inhibited in vitro) and good drug 
uptake/delivery ability (in this study ofloxacin), Cu-MBG coating could be a promising, 
multifunctional tool for the prevention of implant-related infections. 
In a recent patent, Baino et al. [169] proposed the deposition of an antiseptic silver 
nanoclusters/silica composite layer on the surface of orbital implants and ocular prostheses to limit 
the problems of intra- and postoperative bacterial colonization. This nanocomposite oxide-based 
coating is produced by co-sputtering from silver and silica targets, and its thickness can be properly 
modulated in the 1-1000 nm range. A few studies demonstrated that this type of coatings generally 
exhibits a good adhesion on a wide range of substrates (glasses, crystalline ceramics, polymers) and 
allows a prolonged release of silver ions to be maintained in a biological environment (up to 1 
month) [170-172]. In comparison to antibiotics administration, the use of metal ions as antibacterial 
agents (in this case silver) makes it possible to overcome the problems of bacterial resistance and 
could be effective also against antibiotic-resistant bacterial strains. However, the ocular 
environment is highly complex and a number of parameters should be taken in account, such as the 
long-term solubility of the coating, the interaction of metal ions with the tears, the fate of the 
released ions and the possibility of ion-induced tissue necrosis. The strategy of depositing a slowly 
soluble antibacterial coating will deserve further investigation as it could be particularly useful for 
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those ceramic devices, such as porous orbital implants, that should possess a non-absorbable 
skeleton and maintain adequate structural/mechanical integrity over time. 
 
5. Conclusions 
 
The role of ceramics in medicine is traditionally associated to the repair of hard tissues in 
orthopaedics and dentistry; however, they can have a great potential also in other clinical areas, 
such as OOS, due to a set of unique properties that can be successfully exploited for these 
unconventional applications. Unlike metals and polymers, calcium orthophosphates and bioactive 
glasses can bond to host bone and promote new tissue regeneration, which is a key feature for 
implants devoted to the repair of eye orbit bone fractures. Porous ceramics such as HA and alumina 
have been shown to allow fibrovascular ingrowth, which is a fundamental characteristic to ensure a 
safe stability of orbital implants in situ and to reduce the risk of postoperative infection. Novel 
perspectives could raise from the use of nanoceramics such as nano-sized HA, exhibiting an 
enhanced bone-bonding ability compared to conventional clinically-used HA, and mesoporous 
glasses for in situ drug release. Furthermore, bioactive glasses doped with proper metal oxides (e.g. 
CuO) could be exploited to elicit a local antiseptic effect via the release of antibacterial ions. 
Deposition of antiseptic oxide-based coatings on orbital implants could also be a valuable option to 
discourage bacterial infections, which represent a serious problem in OOS. As witnessed by the 
history of biomaterials science, cross-fertilization between different disciplines (materials science, 
cell biology, mechanical engineering, medicine) is essential so that research can proceed; therefore, 
in the next years an increasing collaboration among ceramic scientists, biologists, ophthalmologists 
and maxillofacial surgeons is more than desirable to accelerate the development of new, once 
unexpected strategies to improve the performances of medical ceramics and, consequently. the life 
quality of the patients. 
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Figure legends 
 
Fig. 1. Overview of biocompatible ceramics used in oculo-orbital surgery. 
 
Fig. 2. Synthetic HA scaffolds fabricated by direct ink writing for potential use in craniofacial 
surgery and orbital floor reconstruction: (a) macrophotograph showing the gradient of porosity of 
the implant, (b) ordered porous pattern of stacked HA rods, (c) fracture surface showing the 
connections between two HA rods in adjacent layers, (d) higher magnification view of HA rod 
surface showing an interconnected (partially sintered) network of HA particles (roughly 2 µm in 
size) with intervening fine-scale porosity (images adapted from Simon et al. [49] © Elsevier). 
 
Fig. 3. Bioactive glasses in orbital bone reconstruction: (a) cast S53P4 glass transparent plates with 
their corresponding ‘‘kidney-shaped’’ and ‘‘drop-shaped’’ stainless steel moulds and (b) CT scan 
taken 2 years after orbital floor reconstruction with a 25 mm × 2 mm S53P4 glass implant (white 
arrow) (images adapted from Peltola et al. [54] © American Association of Oral and Maxillofacial 
Surgeons); (c) 45S5 Bioglass® cellular structure fabricated by lithography-based additive 
manufacturing after sintering and (d) proposal for a customized implant for orbital floor repair 
(images adapted from Tesavibul et al. [55] © Elsevier).  
 
Fig. 4. HA/PE composites: (a) HAPEX® implant in the orbital floor of a patient who has lost the 
right eye (the implant is shown with the same radiographic density as the bone to which it is 
bonded, while the spherical black object is a glass ball implanted earlier to restore the volume of the 
orbital socket) (adapted from Tanner [60] © The Royal Society); (b) optical cross-section of 
sintered HA (20 vol.%)/PE composite showing the porous structure with interconnected pores 
(infiltrated by resin) after selective laser sintering (the particles are well fused to each other and 
formed strong boundaries between them); (c) and (d) show the microstructure, at higher 
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magnification, of the areas marked by the rectangles in (b) and (c), respectively (scale bars 50, 50 
and 10 µm respectively) (images adapted from Zhang et al. [59] © Wiley Periodicals). 
 
Fig. 5. Synthetic HA orbital implant: (a) appearance of a porous sphere and (b) planar 
reconstruction of its microstructure by micro-CT (courtesy of Lukats et al. [107]); (c) SEM 
micrograph of a HA implants obtained by using naphthalene as a pore former (the macropores are 
in the 100-300 µm range) (images adapted from Kundu et al. [110] © Indian Academy of Science). 
 
Fig. 6. Reconstruction by cone beam computed tomography (CBCT) of a synthetic HA porous 
sphere implanted in the right orbit of a human patient where the red zones represent the areas of 
fibrovascularization that starts at the implant periphery; the vitreous body of the contralateral eye is 
represented as a grey sphere (courtesy of Lukats et al. [107]). 
 
Fig. 7. Model for cell alignment on a nanogrooved substrate. (a) Actin filaments parallel to the 
grooves form wide focal adhesions at filament terminations. On the other hand, termination of 
perpendicular filaments is fragmented because focal adhesion is formed only on the ridge. (b) 
Filopodia movements are isotropic, i.e. no specific direction is observed for their extension and 
retraction against the nanogrooved structure. This finding suggests that filopodia probing does not 
play a major role in cell alignment. Cell protrusions extend isotropically, but some that are 
perpendicular to the nanogrooved pattern retract more rapidly than those parallel to the 
nanogrooved pattern. These cell protrusion dynamics force a cell to elongate and align along the 
nanogrooved pattern (image adapted from Fujita et al. [153] © The Royal Society). 
 
Fig. 8. MBG-coated porous HA scaffolds for possible use as orbital implants: (a) SEM micrograph 
of the surface and (b) detail of the HA/Cu-doped (5 mol.%) MBG interface; (c) TEM picture of the 
mesoporous texture of the coating (images adapted from Ye et al. [166] © Springer). 
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Tables 
 
Table 1. Ceramics and composites used to produce orbital floor grafts (the implant are often cut and contoured by the surgeon just before operation 
to match the defect size and shape). 
Class of ceramics Material Type of implant Recipient Remarks References 
Natural ceramic-
based materials 
(apatites of 
biological origin) 
Autologous human bone Shapable sheet Human Resorption rate depending on bone type (cancellous, 
cortical) and source (harvesting site). 
[14-35] 
 Bone homograft Shapable sheet Human Allogenic bone banks are available to surgeons. [12,18] 
 Bovine bone Shapable sheet Human Resorpton rate faster than human host bone. [43] 
 Coralline HA porous 
plates 
Porous plate Human Commercial product: Biocoral®. Problems of brittleness 
upon implantation. 
[44,45] 
 Algae-derived HA Porous plate Human Commercial product: AlgOss-C Graft/Algipore) implant [46] 
Synthetic calcium 
phosphates 
Synthetic HA Porous plate Human Problems of brittleness during implantation. [47-50] 
Bioactive glasses Melt-derived S53P4 
glass 
Solid plate Human Slowly resorbable. [51-54] 
 45S5 Bioglass® Mesh - No biological studies are available yet. [55] 
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Composites HA/PE Porous plates Human Commercial product: HAPEX® [57-60] 
 Periosteum joined to a 
HA/PLLA/PCL sheet 
Sheet Human Absorbable implant. [61] 
 HA/PLLA Plate Human  [62] 
 HA cements Mouldable paste Human  [63-66,68] 
 β-TCP/HA biphasic 
calcium phosphate 
Porous plate Cats  [69-71] 
 β-TCP/poly(trimethylene 
carbonate) 
Sheet - No biological evaluation has been reported yet. [72] 
 Fibrin-rich β-TCP/HA 
biphasic calcium 
phosphate 
Mouldable paste Human  [73] 
 Alumina/PTFE (Proplast 
II) 
Sheet Human Currently abandoned. [74] 
 HA nanoparticles/cyclic 
acetal hydrogels 
Sheet Rabbit  [164] 
 
 
 
 
51 
 
Table 2. Ceramics and composites used to produce orbital implants.  
Class of ceramics Material Type of implant Recipient Remarks References 
Biological 
apatites 
Ivory Solid sphere Human Used till the WWII and then abandoned. [81] 
 HA derived from heat-
treated bovine bone 
Porous sphere of charred 
cancellous bone 
Human Used till the WWII and considered an excellent alternative 
to blown glass orbital implants. 
[81-84] 
 Bovine bone-derived HA Porous sphere Human Commercial product: Molteno M-Sphere. [85-90] 
 Coralline HA Porous sphere, egg-shaped 
porous implants 
Human Commercial product: Bio-Eye®. [91-104] 
Synthetic calcium 
phosphates 
Synthetic HA Porous sphere, egg-shaped 
porous implants 
Human Mostly used commercial products: FCI3. Few less expensive 
implants are available worldwide, especially in emerging 
countries (with problems associated with low purity of HA). 
[105-114] 
Bioinert ceramics Alumina Porous sphere Human Commercial product: Bioceramic implant. [115-125] 
Glasses and glass-
ceramics 
Common silicate glass 
(non-crystalline ceramic) 
Blown sphere Human First implant used by Mules in evisceration procedures 
(1885). The “Mules implant” and its evolutions were the 
most commonly used devices till the WWII.   
[77] 
 Porous glass/glass-
ceramic 
Porous sphere  Human Promising results. [126-128] 
 Biosilicate® Dense (pore-free) cones Rabbit, human Early clinical trials in humans are currently on going in 
Brazil. 
[131,132] 
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 Bioactive glass Additive in HA implants to 
fill old peg tracts 
Human Good outcomes [133] 
Composites Carbon/PTFE composite 
(Proplast I) 
Hemispherical implants Human Despite the fibrovascular ingrowth and generally good 
outcomes, it was abandoned in the 1980s due to the risk of 
late infections.  
[134,135] 
 Alumina/PTFE 
composite (Proplast II) 
Porous implant having a 
siliconized non-porous 
posterior surface to allow 
smoother movements 
Human It was abandoned due to poor motility and absence of 
fibrovascular ingrowth. 
[137-139] 
 HA/silicone Implant comprising a 
hemispherical anterior part 
made of synthetic porous 
HA and a posterior part 
made of silicone rubber 
Human Commonly known as “Guthoff implant”. It exhibits good 
postoperative outcomes but has high cost and requires 
complex surgical procedures of implantation.  
[140-142] 
 Bioactive glass/PE Porous sphere Human Absence of a clear improvement in implant 
fibrovascularization with respect to porous PE. 
[143,144] 
 HA-coated alumina  Porous sphere Rabbit Absence of a clear advantage over bare alumina orbital 
implants. 
[145-148] 
 HA coated with Cu-
containing mesoporous 
Porous sphere In vitro tests Encouraging antibacterial results against S. Aureus and E. 
Coli 
[166] 
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bioactive glass 
 
 
Table 3. Major characteristics of today’s commercially-available ceramic porous orbital implants (many sizes are available to meet the patient’s 
needs; sphere diameters are typically in the 10-22 mm range). 
Commercial product 
(material) 
Porosity (vol.%) Pore size (µm) Surface characteristics Remarks References 
Molteno M-sphere 
(bovine bone-derived 
HA) 
> 80 > 300 Nanocrystalline structure of bone 
apatite.  
Problems of brittleness upon 
implantation, difficult pegging. 
[89] 
Bio-Eye® (coralline HA) ~65 300-700 Irregular micro-crystals of HA with 
size around 2 µm. 
Problems of conjunctival abrasion and 
associated implant exposure. 
[106] 
FCI3 (synthetic HA) ~50 300-500 Hexagonal micro-crystals of HA with 
size within 1-5 µm. 
Problems of conjunctival abrasion and 
associated implant exposure. 
[106] 
Bioceramic implant 
(alumina) 
> 75 500 Cobblestone pattern of ultrafine micro-
crystals in the 0.4-1.1 µm range. 
Promising results; very limited 
problems of conjunctival abrasion due 
to the small size of surface crystals.  
[118] 
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